Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET : revenue, balance sheet and financial ratios

SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET is a French company founded 31 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in PODENSAC (33720), this company of category PME shows in 2023 a revenue of 4.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET (SIREN 401489059)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C 4 196 458 € N/C N/C N/C N/C N/C N/C
Net income 361 086 € 352 008 € 358 677 € 433 823 € 292 357 € 308 180 € 303 704 € 281 031 € 242 775 €
EBITDA N/C N/C 479 125 € N/C N/C N/C N/C N/C N/C
Net margin N/C N/C 8.5% N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET generates positive net income of 361 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 243 k€ -> 361 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

361 086 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 16%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 72%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

15.765%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

72.442%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

76.5%

Solvency indicators evolution
SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET

Sector positioning

Debt ratio
15.77 2025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Good

In 2025, the debt ratio of SOCIETE D'EXERCICE LIBERA... (15.77) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
72.44% 2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Excellent

In 2025, the financial autonomy of SOCIETE D'EXERCICE LIBERA... (72.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.72 years 2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Excellent

In 2023, the repayment capacity of SOCIETE D'EXERCICE LIBERA... (0.72) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 304.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

304.471

Liquidity indicators evolution
SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET

Sector positioning

Liquidity ratio
304.47 2025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Excellent

In 2025, the liquidity ratio of SOCIETE D'EXERCICE LIBERA... (304.47) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.04x 2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average

In 2023, the interest coverage of SOCIETE D'EXERCICE LIBERA... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET

Positioning of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET is estimated at 5 735 894 € (range 3 892 404€ - 9 000 407€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
3892k€ 5735k€ 9000k€
5 735 894 € Range: 3 892 404€ - 9 000 407€
NAF 5 année 2025

Valuation method used

Net Income Multiple
361 086 € × 15.9x = 5 735 894 €
Range: 3 892 405€ - 9 000 408€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET

What is the revenue of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET ?

The revenue of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET in 2023 is 4.2 M€.

Is SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET profitable?

Yes, SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET generated a net profit of 361 k€ in 2025.

Where is the headquarters of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET ?

The headquarters of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET is located in PODENSAC (33720), in the department Gironde.

Where to find the tax return of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET ?

The tax return of SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET operate?

SOCIETE D'EXERCICE LIBERAL PAR ACTIONS SIMPLIFIE DE PHARMACIENS-PHARMACIE RIBOULLEAU JACQUET operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.